Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Journal
Gastroenterology
Journal Volume
165
Journal Issue
6
Pages
1443
Date Issued
2023-12
Author(s)
Peyrin-Biroulet, Laurent
Allegretti, Jessica R
Rubin, David T
Bressler, Brian
Germinaro, Matthew
Huang, Kuan-Hsiang Gary
Shipitofsky, Nicole
Zhang, Hongyan
Wilson, Rebbecca
Han, Chenglong
Feagan, Brian G
Sandborn, William J
Panés, Julian
Hisamatsu, Tadakazu
Lichtenstein, Gary R
Sands, Bruce E
Dignass, Axel
Abstract
The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy.
Subjects
Advanced Therapy; Interleukin-23p19 Subunit Antagonist; QUASAR; Ulcerative Colitis
Type
journal article